EX-16.1 2 ea137211ex16-1_nlspharma.htm LETTER FROM MARCUM LLP. ADDRESSED TO THE U.S. SECURITIES AND EXCHANGE COMMISSION DATED MARCH 10, 2021.

 

Exhibit 16.1

 

 March 10, 2021

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by NLS Pharmaceutics Ltd. under “Changes in Company’s Certifying Accountant” on its Form 6-K dated March 10, 2021. We agree with the statements concerning our Firm in such Form 6-K; we are not in a position to agree or disagree with other statements of NLS Pharmaceutics Ltd. contained therein.

 

Very truly yours,

 

/s/ Marcum llp

 

Marcum llp